Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Author's Avatar
Aug 11, 2022

Virios+Therapeutics%2C+Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia, today announced financial results for the second quarter ended June 30, 2022.